TY - JOUR
T1 - Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
AU - Aliberti, Stefano
AU - Ringshausen, Felix C
AU - Dhar, Raja
AU - Haworth, Charles S
AU - Loebinger, Michael R
AU - Dimakou, Katerina
AU - Crichton, Megan L
AU - De Soyza, Anthony
AU - Vendrell, Montse
AU - Burgel, Pierre-Regis
AU - McDonnell, Melissa
AU - Skrgat, Sabina
AU - Maiz Carro, Luis
AU - de Roux, Andres
AU - Sibila, Oriol
AU - Bossios, Apostolos
AU - van der Eerden, Menno
AU - Kauppi, Paula
AU - Wilson, Robert
AU - Milenkovic, Branislava
AU - Menendez, Rosario
AU - Murris, Marlene
AU - Borekci, Sermin
AU - Munteanu, Oxana
AU - Obradovic, Dusanka
AU - Nowinski, Adam
AU - Amorim, Adelina
AU - Torres, Antoni
AU - Lorent, Natalie
AU - Van Braeckel, Eva
AU - Altenburg, Josje
AU - Shoemark, Amelia
AU - Shteinberg, Michal
AU - Boersma, Wim
AU - Goeminne, Pieter C
AU - Elborn, J Stuart
AU - Hill, Adam T
AU - Welte, Tobias
AU - Blasi, Francesco
AU - Polverino, Eva
AU - Chalmers, James D
AU - EMBARC Registry Investigators
PY - 2024/4/18
Y1 - 2024/4/18
N2 - Background: A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the European Bronchiectasis Registry (EMBARC), we tested whether sputum colour would be associated with disease severity and clinical outcomes.Methods: We used a prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits. Key outcomes were frequency of exacerbations, hospitalisations for severe exacerbations and mortality during up to 5-year follow-up.Results: 13 484 patients were included in the analysis. More purulent sputum was associated with lower forced expiratory volume in 1 s (FEV1), worse quality of life, greater bacterial infection and a higher bronchiectasis severity index. Sputum colour was strongly associated with the risk of future exacerbations during follow-up. Compared to patients with mucoid sputum (reference group), patients with mucopurulent sputum experienced significantly more exacerbations (incident rate ratio (IRR) 1.29, 95% CI 1.22–1.38; p<0.0001), while the rates were even higher for patients with purulent (IRR 1.55, 95% CI 1.44–1.67; p<0.0001) and severely purulent sputum (IRR 1.91, 95% CI 1.52–2.39; p<0.0001). Hospitalisations for severe exacerbations were also associated with increasing sputum colour with rate ratios, compared to patients with mucoid sputum, of 1.41 (95% CI 1.29–1.56; p<0.0001), 1.98 (95% CI 1.77–2.21; p<0.0001) and 3.05 (95% CI 2.25–4.14; p<0.0001) for mucopurulent, purulent and severely purulent sputum, respectively. Mortality was significantly increased with increasing sputum purulence, hazard ratio 1.12 (95% CI 1.01–1.24; p=0.027), for each increment in sputum purulence.Conclusion: Sputum colour is a simple marker of disease severity and future risk of exacerbations, severe exacerbations and mortality in patients with bronchiectasis.
AB - Background: A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the European Bronchiectasis Registry (EMBARC), we tested whether sputum colour would be associated with disease severity and clinical outcomes.Methods: We used a prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits. Key outcomes were frequency of exacerbations, hospitalisations for severe exacerbations and mortality during up to 5-year follow-up.Results: 13 484 patients were included in the analysis. More purulent sputum was associated with lower forced expiratory volume in 1 s (FEV1), worse quality of life, greater bacterial infection and a higher bronchiectasis severity index. Sputum colour was strongly associated with the risk of future exacerbations during follow-up. Compared to patients with mucoid sputum (reference group), patients with mucopurulent sputum experienced significantly more exacerbations (incident rate ratio (IRR) 1.29, 95% CI 1.22–1.38; p<0.0001), while the rates were even higher for patients with purulent (IRR 1.55, 95% CI 1.44–1.67; p<0.0001) and severely purulent sputum (IRR 1.91, 95% CI 1.52–2.39; p<0.0001). Hospitalisations for severe exacerbations were also associated with increasing sputum colour with rate ratios, compared to patients with mucoid sputum, of 1.41 (95% CI 1.29–1.56; p<0.0001), 1.98 (95% CI 1.77–2.21; p<0.0001) and 3.05 (95% CI 2.25–4.14; p<0.0001) for mucopurulent, purulent and severely purulent sputum, respectively. Mortality was significantly increased with increasing sputum purulence, hazard ratio 1.12 (95% CI 1.01–1.24; p=0.027), for each increment in sputum purulence.Conclusion: Sputum colour is a simple marker of disease severity and future risk of exacerbations, severe exacerbations and mortality in patients with bronchiectasis.
KW - Bronchiectasis - diagnosis - microbiology
KW - Humans
KW - Registries
KW - Sputum - microbiology
KW - Color
KW - Calcium Phosphates
KW - Adult
KW - Quality of Life
KW - Prospective Studies
U2 - 10.1183/13993003.01554-2023
DO - 10.1183/13993003.01554-2023
M3 - Article
C2 - 38609095
SN - 0903-1936
VL - 63
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 4
M1 - 2301554
ER -